{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:14:06Z","timestamp":1789884846608,"version":"4.0.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clml.2026.03.007","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:13:30Z","timestamp":1773681210000},"page":"e740-e751.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Changes in Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-ITD-mutated Acute Myeloid Leukemia in the FLT3 Inhibitor Era"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0973-6363","authenticated-orcid":false,"given":"Atsushi","family":"Jinguji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6426-6770","authenticated-orcid":false,"given":"Shuhei","family":"Kurosawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7436-972X","authenticated-orcid":false,"given":"Takashi","family":"Toya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Sadaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6009-2688","authenticated-orcid":false,"given":"Kaori","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Ouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Shimabukuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7723-0897","authenticated-orcid":false,"given":"Naoki","family":"Shingai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8910-0021","authenticated-orcid":false,"given":"Yuho","family":"Najima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3844-9673","authenticated-orcid":false,"given":"Kyoko","family":"Haraguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8661-3179","authenticated-orcid":false,"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.03.007_bib0001","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.03.007_bib0002","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.03.007_bib0003","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3324\/haematol.2019.243410","volume":"105","author":"Bazarbachi","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.03.007_bib0004","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2011.36.9868","article-title":"Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis","volume":"30","author":"Brunet","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.03.007_bib0005","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2014-05-578070","article-title":"Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation","volume":"124","author":"Schlenk","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.007_bib0006","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/bmt.2015.170","article-title":"FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML","volume":"51","author":"Song","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2026.03.007_bib0007","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1002\/cncr.30140","article-title":"Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis","volume":"122","author":"Deol","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2026.03.007_bib0008","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1111\/cas.14448","article-title":"Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: the JALSG AML209-FLT3-SCT study","volume":"111","author":"Kawashima","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2026.03.007_bib0009","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41375-019-0694-3","article-title":"FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions","volume":"34","author":"Antar","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.03.007_bib0010","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12185-022-03352-6","article-title":"FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation","volume":"116","author":"Biavasco","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2026.03.007_bib0011","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12185-022-03374-0","article-title":"FLT3-targeted treatment for acute myeloid leukemia","volume":"116","author":"Arai","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2026.03.007_bib0012","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12185-023-03596-w","article-title":"Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS","volume":"118","author":"Najima","year":"2023","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2026.03.007_bib0013","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.03.007_bib0014","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jtct.2022.12.006","article-title":"Outcomes in patients with FLT3-mutated relapsed\/refractory acute myelogenous leukemia who underwent transplantation in the phase 3 ADMIRAL trial of gilteritinib versus salvage chemotherapy","volume":"29","author":"Perl","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2026.03.007_bib0015","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2026.03.007_bib0016","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for acute myeloid leukemia with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.03.007_bib0017","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood.2024025154","article-title":"Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML","volume":"145","author":"Levis","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.007_bib0018","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1182\/bloodadvances.2025016306","article-title":"Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia","volume":"9","author":"Levis","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.03.007_bib0019","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ajh.26451","article-title":"Improved outcomes among newly diagnosed patients with <scp>FMS-like tyrosine kinase 3 internal tandem duplication<\/scp>mutated acute myeloid leukemia treated with contemporary therapy: revisiting the European LeukemiaNet adverse risk classification","volume":"97","author":"Reville","year":"2022","journal-title":"American Journal of Hematology"},{"key":"10.1016\/j.clml.2026.03.007_bib0020","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1158\/1078-0432.CCR-23-0954","article-title":"Improved posttransplant outcomes in recent years for AML patients with FLT3-ITD and Wild-type NPM1: a report from the EBMT acute leukemia working party","volume":"29","author":"Bazarbachi","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2026.03.007_bib0021","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-023-00839-1","article-title":"Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort","volume":"13","author":"Onate","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.03.007_bib0022","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1038\/s41409-021-01475-8","article-title":"Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation","volume":"56","author":"Liang","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2026.03.007_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100141","article-title":"Three-year follow-up of low-dose, early-start gilteritinib maintenance in posttransplant patients with R\/R FLT3 mut AML","volume":"2","author":"Terao","year":"2025","journal-title":"Blood Neoplasia"},{"key":"10.1016\/j.clml.2026.03.007_bib0024","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2220518","article-title":"Bridging to transplant and post-transplant maintenance therapy with FLT3 inhibitors in patients with relapsed or refractory FLT3 mutated acute myeloid leukemia","volume":"28","author":"Hirose","year":"2023","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2026.03.007_bib0025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.21037\/atm-23-1941","article-title":"FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML) patients","volume":"12","author":"He","year":"2024","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.clml.2026.03.007_bib0026","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/jha2.885","article-title":"Post-stem cell transplant maintenance in FLT3(mut) acute myeloid leukemia - A retrospective analysis: outcomes are improved with midostaurin but not with gilteritinib","volume":"5","author":"Ashouri","year":"2024","journal-title":"EJHaem"},{"key":"10.1016\/j.clml.2026.03.007_bib0027","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2025.2509353","article-title":"Gilteritinib maintenance after allogeneic hematopoietic stem cell transplantation for relapsed\/refractory acute myeloid leukemia with FLT3-internal tandem duplication mutation","volume":"30","author":"Liang","year":"2025","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2026.03.007_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1521895","article-title":"Changes in donor lymphocyte infusion for relapsed patients post-hematopoietic stem cell transplantation: a 30-year single-center experience","volume":"16","author":"Uchibori","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2026.03.007_bib0029","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/s41409-025-02625-y","article-title":"Improved non-relapse mortality in allogeneic hematopoietic stem cell transplantation: a long-standing multidisciplinary pursuit at a single center","volume":"60","author":"Kurosawa","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2026.03.007_bib0030","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jtct.2025.04.016","article-title":"Recent advances in the prognosis of HHV-6 encephalitis following allogeneic hematopoietic stem cell transplantation","volume":"31","author":"Kurihara","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2026.03.007_bib0031","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1007\/s12185-025-03951-z","article-title":"Transplantation outcomes of TP53-mutant AML and MDS: a single transplantation center experience of 63 patients","volume":"121","author":"Masuda","year":"2025","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2026.03.007_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2025.107704","article-title":"Pre-transplant blinatumomab and\/or inotuzumab ozogamicin therapy for relapsed\/refractory acute lymphoblastic and B\/myeloid mixed phenotype acute leukemia in adults","volume":"153","author":"Kondo","year":"2025","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2026.03.007_bib0033","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clml.2026.03.007_bib0034","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.007_bib0035","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.007_bib0036","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.007_bib0037","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.03.007_bib0038","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2026.03.007_bib0039","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2026.03.007_bib0040","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.clml.2019.04.005","article-title":"Allogeneic stem cell transplantation in patients with FLT3-ITD mutated AML: transplantation in CR1 is the decisive factor for good outcome","volume":"19","author":"Jindra","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.03.007_bib0041","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jtct.2024.04.016","article-title":"Clinical outcomes and treatment patterns in adults with FLT3-ITD(mut+) acute myeloid leukemia undergoing allogeneic hemopoietic cell transplantation in the United States and Canada","volume":"30","author":"Pandya","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2026.03.007_bib0042","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/j.bbmt.2019.04.025","volume":"25","author":"Harada","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2026.03.007_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106701","article-title":"Mutational profiling of myeloid neoplasms associated genes may aid the diagnosis of acute myeloid leukemia with myelodysplasia-related changes","volume":"110","author":"Yu","year":"2021","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2026.03.007_bib0044","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41408-022-00774-7","article-title":"Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML","volume":"13","author":"Tsai","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.03.007_bib0045","doi-asserted-by":"crossref","first-page":"5354","DOI":"10.1182\/bloodadvances.2023009748","article-title":"FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged >\/=60 years","volume":"7","author":"Shimony","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.03.007_bib0046","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/bloodadvances.2023011869","article-title":"A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria","volume":"8","author":"Zhou","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.03.007_bib0047","first-page":"115","article-title":"Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry","volume":"109","author":"Martinez-Cuadron","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.03.007_bib0048","doi-asserted-by":"crossref","DOI":"10.1111\/tid.70116","article-title":"Real-world efficacy of extending duration of letermovir prophylaxis for allogeneic stem cell recipients","volume":"27","author":"Masuda","year":"2025","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.clml.2026.03.007_bib0049","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s12185-016-1947-9","article-title":"Impact of low-dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation","volume":"103","author":"Kuriyama","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2026.03.007_bib0050","first-page":"2024","article-title":"Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial","volume":"110","author":"Schlenk","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.03.007_bib0051","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jtct.2022.12.006","article-title":"Outcomes in patients with FLT3-mutated relapsed\/refractory acute myelogenous leukemia who underwent transplantation in the phase 3 ADMIRAL trial of Gilteritinib versus Salvage Chemotherapy","volume":"29","author":"Perl","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2026.03.007_bib0052","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm.4484","article-title":"Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2026.03.007_bib0053","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41409-022-01619-4","article-title":"Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation","volume":"57","author":"Zhang","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2026.03.007_bib0054","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s40262-020-00888-w","article-title":"Pharmacokinetic profile of Gilteritinib: a novel FLT-3 tyrosine kinase inhibitor","volume":"59","author":"James","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clml.2026.03.007_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106610","article-title":"Triazole antifungal use for prophylaxis and treatment of invasive fungal diseases for patients receiving gilteritinib","volume":"108","author":"Aleissa","year":"2021","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2026.03.007_bib0056","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/jjco\/hyac069","article-title":"Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed\/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan","volume":"52","author":"Sugamori","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clml.2026.03.007_bib0057","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41409-020-01016-9","article-title":"Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT","volume":"56","author":"Najima","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2026.03.007_bib0058","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1038\/s41598-023-29794-4","article-title":"Impact of gene alterations on clinical outcome in young adults with myelodysplastic syndromes","volume":"13","author":"Konishi","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.clml.2026.03.007_bib0059","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41375-024-02152-7","article-title":"Recurrent DDX41 mutation in very late relapse after allogeneic stem cell transplantation","volume":"38","author":"Kambara","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.03.007_bib0060","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood.2019002697","article-title":"Impact of NPM1\/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia","volume":"135","author":"D\u00f6hner","year":"2020","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:06:07Z","timestamp":1781251567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026000728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2152265026000728"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-ITD-mutated Acute Myeloid Leukemia in the FLT3 Inhibitor Era","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}